JPM2025预览报告

#JPM2025Preview Report #JPM2025PreviewReport Biotech Enters A New Era Of AI-Driven Drug Development Foreword by Chris Smyth, President, ICON Biotech Automated technologies, such as artificial intelligence (AI), have served as a majorcatalyst for biotech innovation in the last few years. From facilitating the developmentof advanced and combination therapies across areas of high unmet need to supportingmore patient-centric approaches to clinical trial design and management, there hasbeen significant progress in the development of personalized medicine, thanks to AI-powered breakthroughs in drug discovery and predictive analytics. While AI is driving greater efficiencies for biotech companies, we are continuing to seesome of the same core issues in this space, including financial scalability, lack ofspecialized talent and complex regulatory landscapes, still hindering the path to thepatient. Moreover, uncertainty around the BIOSECURE Act looms large. These aspectsof clinical development are becoming bigger pain points as innovation amplifies,especially for smaller biotech companies. Amid this technological revolution, ICON – the world’s largest clinical researchorganization (CRO) – provides support and expertise to help companies mitigate thecosts and risks associated with clinical development. We provide flexible partnershipmodels that inform decision-making through extensive data resources and integratedclinical capabilities. With our dedicated biotech division, ICON Biotech, we arecommitted to meeting the individualized needs of life sciences organizations. The upcoming 43rdAnnual J.P. Morgan Healthcare Conference is an opportunity tocollaborate with key opinion leaders through discussions on current and future barriersto drug development, and ways to anticipate and address them. We are eager toexplore the AI pipeline, industry perspectives on AI integration and the expectedimpact of AI on the biotech sector moving forward. There is nothing more important to us than helping organizations deliver life-savingtreatments to patients. Now that advanced technologies have changed the game,forming partnerships has never been more critical to making scientific discoveries areality. By connecting with like-minded individuals, we can exchange knowledge andwork together to form solutions that will improve healthcare and patient outcomesacross the globe. We are pleased to partner with Citeline to deliver the following preview coverage of theJ.P. Morgan Healthcare Conference. To learn more about ICON Biotech, visit us atwww.iconplc.com/biotech. Summary The 43rd annual J.P. Morgan Healthcare Conference (JPM) is being held in San Francisco, CAover January 13-16, 2025. Before the meeting kicks off, we have chosen a few companies towatch throughout the week to prime you for the jam-packed conference. Here we summarizethe current affairs surrounding these companies and potential discussion points to bepresented. Stay tuned for Biomedtracker’s full real-time coverage of the 2025 J.P. Morgan HealthcareConference. Our daily reports published each evening will bring you the important pipelineupdates and key takeaways from the entire day’s presentations. With our platforms helping younavigate along the way, you’ll stay informed on the latest updates in drug development and notmiss a beat from the biggest investor healthcare conference of the year. About the Author Biomedtrackeris an independent research service that offers proprietary clinical assessmentsand patient-based revenue forecasts of developmental drugs within a comprehensive andintuitive drug information database. Clients from the pharmaceutical, biotech, and investmentindustries rely on Biomedtracker for its insight on the likelihood of approval, commercialpotential, and future data and regulatory catalysts for drugs within the competitive landscapeof every important disease and indication. Over the last several years, Biomedtracker hasbecome the leader in providing objective information alongside evidencebased clinicalassessments and investment research on pipeline drugs worldwide. For more information ongetting direct access to Biomedtracker, please email clientservices@citeline.com. Disclaimer Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company This report ispublished by Pharma Intelligence (the Publisher). This report contains information fromreputable sources and although reasonable efforts have been made to publish accurateinformation, you assume sole responsibility for the selection, suitability and use of this reportand acknowledge that the Publisher makes no warranties (either express or implied) as to, noraccepts liability for, the accuracy or fitness for a particular purpose of the information or advicecontained herein. The Publisher wishes to make it clear that any views or opinions expressed inthis report by individual authors or contributors are their personal views and opinions and donot necessarily reflect the